GSK:NYSE
GSK plc
$49.89
arrow_downward
-1.93%(-0.98) 1D
$49.91
arrow_upward
+0.04% (+0.020)bedtimeAfter hours
Closed: Sep 4, 4:00:03 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$49.70
High
$50.06
Low
$49.66
Mkt. cap
99.85B
Avg. vol.
3.63M
Volume
2.29M
Dividend
3.64%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
15.68
52-wk high
$61.70
52-wk low
$39.29
EPS
$3.18
Beta
0.27
Shares outstanding
2.02B
No. of employees
67K
Open
$49.70
High
$50.06
Low
$49.66
Mkt. cap
99.85B
Avg. vol.
3.63M
Volume
2.29M
Dividend
3.64%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
15.68
52-wk high
$61.70
52-wk low
$39.29
EPS
$3.18
Beta
0.27
Shares outstanding
2.02B
No. of employees
67K
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
GSK stock gains on Nuvalent oncology deal and steady outlook
AD HOC NEWS
·
1 day ago
HCM stock gains on GSK oncology deal and fresh guidance
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
Analyst ratings
Based on 2 analysts giving stock ratings to GSK in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GSK in the last 3 months.
Highest
Current $49.89
$70.00 (+40.31%)
Average
$70.00 (+40.31%)
Lowest
$70.00 (+40.31%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Steve Scala TD Cowen | Buy | Maintained | $70.00 | +40.3% | 08/25/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | - | - | 06/08/2026 |
Michael Leuchten Jefferies | Buy | Maintained | $67.10 | +34.5% | 05/29/2026 |
Unknown Analyst Berenberg Bank | Hold | Maintained | $54.00 | +8.2% | 03/26/2026 |
Unknown Analyst Citi | Hold | Initiated | - | - | 01/29/2026 |
Last report
Jul 28, 2026
Fiscal period
Q2 2026
EPS / Est. (GBP)
£1.01 / £0.48
+110.86%beat
arrow_upward
Revenue / Est. (GBP)
8.41B / 8.32B
+1.03%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in GBP | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 8.55B | 8.62B | 7.63B | 8.41B |
Cost of goods sold | 2.24B | 2.62B | 1.87B | 2.07B |
Cost of revenue | 2.24B | 2.62B | 1.87B | 2.07B |
Research and development expenses | 1.58B | 2.14B | 1.52B | 1.75B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.16B | 2.67B | 2.08B | 2.19B |
Operating expense | 3.23B | 4.37B | 2.99B | 3.74B |
Total operating expenses | 5.46B | 6.99B | 4.86B | 5.81B |
Operating income | 3.08B | 1.63B | 2.77B | 2.60B |
Other non operating income | - | -21.00M | - | - |
EBT including unusual items | 2.46B | 950.00M | 2.14B | 354.00M |
EBT excluding unusual items | 2.94B | 1.48B | 2.62B | 2.48B |
Income tax expense | 312.00M | 223.00M | 305.00M | -199.00M |
Effective tax rate | 12.70% | 23.47% | 14.23% | -56.21% |
Other operating expenses | -511.00M | -434.00M | -615.00M | -204.00M |
Net income | 2.01B | 636.00M | 1.74B | 435.00M |
Net profit margin | 23.55% | 7.38% | 22.77% | 5.17% |
Earnings per share | 0.55 | - | - | - |
Interest and investment income | 26.00M | 17.00M | 22.00M | 58.00M |
Interest expense | -167.00M | -145.00M | -167.00M | -182.00M |
Net interest expenses | -141.00M | -128.00M | -145.00M | -124.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 3.82B | 2.69B | 3.23B | 2.82B |
Gain or loss from assets sale | - | -40.00M | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1